Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1601-1610 of 1,873) with videos related to

Pageof 188
Sort By:
JACC. Heart Failure|June 10, 2025
Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of 4 Contemporary TrialsMats C H Lassen, John W Ostrominski, Brian L Claggett, et al.
Acta Cytologica|February 28, 1998
Cell preparation methods and criteria for sample adequacy. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and TutorialE McGoogan, T J Colgan, I Ramzy, et al.
American Journal of Human Genetics|June 6, 2015
Individualized iterative phenotyping for genome-wide analysis of loss-of-function mutationsJennifer J Johnston, Katie L Lewis, David Ng, et al.
Circulation|August 26, 2023
Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER TrialSafia Chatur, Muthiah Vaduganathan, Brian L Claggett, et al.
European Journal of Heart Failure|May 22, 2023
Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trialsAnkeet S Bhatt, Mikhail N Kosiborod, Muthiah Vaduganathan, et al.
JACC. Heart Failure|March 15, 2025
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HFToru Kondo, Pardeep S Jhund, Inder S Anand, et al.
JAMA Cardiology|March 27, 2024
Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection FractionKirsty McDowell, Toru Kondo, Atefeh Talebi, et al.
Circulation. Heart Failure|June 23, 2023
Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial FibrillationToru Kondo, Karola S Jering, Pardeep S Jhund, et al.
JAMA Cardiology|February 26, 2025
Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical TrialJonathan W Cunningham, Safia Chatur, Brian L Claggett, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR SubstudyAhmad Masri, Rhanderson N Cardoso, Theodore P Abraham, et al.
Pageof 188

Showing results (1601-1610 of 1,873) with videos related to

Sort By:
Pageof 188
JACC. Heart Failure|June 10, 2025
Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of 4 Contemporary TrialsMats C H Lassen, John W Ostrominski, Brian L Claggett, et al.
Acta Cytologica|February 28, 1998
Cell preparation methods and criteria for sample adequacy. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and TutorialE McGoogan, T J Colgan, I Ramzy, et al.
American Journal of Human Genetics|June 6, 2015
Individualized iterative phenotyping for genome-wide analysis of loss-of-function mutationsJennifer J Johnston, Katie L Lewis, David Ng, et al.
Circulation|August 26, 2023
Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER TrialSafia Chatur, Muthiah Vaduganathan, Brian L Claggett, et al.
European Journal of Heart Failure|May 22, 2023
Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trialsAnkeet S Bhatt, Mikhail N Kosiborod, Muthiah Vaduganathan, et al.
JACC. Heart Failure|March 15, 2025
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HFToru Kondo, Pardeep S Jhund, Inder S Anand, et al.
JAMA Cardiology|March 27, 2024
Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection FractionKirsty McDowell, Toru Kondo, Atefeh Talebi, et al.
Circulation. Heart Failure|June 23, 2023
Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial FibrillationToru Kondo, Karola S Jering, Pardeep S Jhund, et al.
JAMA Cardiology|February 26, 2025
Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical TrialJonathan W Cunningham, Safia Chatur, Brian L Claggett, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR SubstudyAhmad Masri, Rhanderson N Cardoso, Theodore P Abraham, et al.
Pageof 188